AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21839410 — intervention group
Group type: COMPARATOR
Intervention: All versions of the PRO instrument
Number of subjects: 0
Study 19886856 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 14
Study 19886856 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 14
Study 16915310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (8-week course)
Number of subjects: 144
Study 16915310 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 14980912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (Group E)
Number of subjects: 120
Study 14980912 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour ambulation (Group 6-h)
Number of subjects: 120
Study 14980912 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ambulation (Group L)
Number of subjects: 120
Study 11258773 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cm excision margin
Number of subjects: 740
Study 11258773 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm excision margin
Number of subjects: 740
Study 11258773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulceration present
Number of subjects: 740
Study 11258773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulceration absent
Number of subjects: 740
Study 11258773 — intervention group
Group type: COMPARATOR
Intervention: Observation of regional lymph nodes
Number of subjects: 740
Study 11258773 — intervention group
Group type: COMPARATOR
Intervention: Elective node dissection of regional lymph nodes
Number of subjects: 740
Study 9152564 — intervention group
Group type: EXPERIMENTAL
Intervention: finasteride
Number of subjects: 2112
Study 9152564 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2112
Study 7898078 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 2.5 mg
Number of subjects: 166
Study 7898078 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5 mg
Number of subjects: 166
Study 7898078 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 166
Study 7898078 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 166
Study 7898078 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 166
Study 7898078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 3278234 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate drops
Number of subjects: 2732
Study 3278234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline ointment
Number of subjects: 2732
Study 29673408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosurgery
Number of subjects: 137
Study 29673408 — intervention group
Group type: COMPARATOR
Intervention: Conventional tangential excision with a knife
Number of subjects: 137
Study 28501369 — intervention group
Group type: EXPERIMENTAL
Intervention: SCREENIVF
Number of subjects: 851
Study 25616822 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 154
Study 25616822 — intervention group
Group type: COMPARATOR
Intervention: Control (no paclitaxel)
Number of subjects: 154
Study 23756271 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg oral misoprostol (two 25 µg tablets)
Number of subjects: 228
Study 23756271 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 µg intravaginal misoprostol (one 25 µg tablet)
Number of subjects: 228
Study 23756271 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 228
Study 21356121 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to water (intervention group)
Number of subjects: 76
Study 21356121 — intervention group
Group type: COMPARATOR
Intervention: Thickened fluids (control group)
Number of subjects: 76
Study 18172906 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg/day)
Number of subjects: 28
Study 18172906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22431674 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring group
Number of subjects: 118
Study 22431674 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives group
Number of subjects: 118
Study 22431674 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 118
Study 16022955 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (METS)
Number of subjects: 11323
Study 16022955 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 11323
Study 16022955 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction (moderate: -6% to -10%; substantial: >-10%)
Number of subjects: 11323
Study 16022955 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 11323
Study 12701817 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (30 g per day for 14 days)
Number of subjects: 12
Study 10462113 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 7
Study 10462113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8900567 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 100
Study 8900567 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 100
Study 2132029 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen infusion (0.3 g/body weight kg/day)
Number of subjects: 20
Study 2132029 — intervention group
Group type: COMPARATOR
Intervention: Low nitrogen infusion (0.1 g/body weight kg/day)
Number of subjects: 20
Study 2132029 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complications (both nitrogen groups)
Number of subjects: 20
Study 347954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 9
Study 347954 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 9
Study 11981237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic doses)
Number of subjects: 8
Study 11981237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31374665 — intervention group
Group type: EXPERIMENTAL
Intervention: hunova® rehabilitation robot
Number of subjects: 0
Study 30170593 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated tobacco products (HTPs)
Number of subjects: 12
Study 30170593 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 12
Study 27525939 — intervention group
Group type: EXPERIMENTAL
Intervention: Upland cotton genotypes
Number of subjects: 16
Study 24907873 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 6.75 mg + 0.3 mL 2% lidocaine (Group L)
Number of subjects: 40
Study 24907873 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 6.75 mg + saline (Group C)
Number of subjects: 40
Study 22215866 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS (2 mA, 15 sessions over 3 weeks)
Number of subjects: 64
Study 22215866 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 64
Study 20308916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion during cardiopulmonary bypass (CPB)
Number of subjects: 106
Study 20308916 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control) during cardiopulmonary bypass (CPB)
Number of subjects: 106
Study 18803987 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg
Number of subjects: 232
Study 18803987 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg
Number of subjects: 232
Study 18803987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 15994073 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 30
Study 15994073 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 30
Study 15994073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12830056 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 438
Study 12830056 — intervention group
Group type: COMPARATOR
Intervention: Right internal thoracic artery
Number of subjects: 438
Study 12830056 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein
Number of subjects: 438
Study 11789170 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention enema with Qilian Liquid (QLL)
Number of subjects: 0
Study 11789170 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9065249 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (M)
Number of subjects: 120
Study 9065249 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (P)
Number of subjects: 120
Study 1380610 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil slow-release (VSR)
Number of subjects: 20
Study 1380610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine plus propranolol (N + P)
Number of subjects: 20
Study 6359845 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 45
Study 6359845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 45
Study 6359845 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (V)
Number of subjects: 45
Study 31651403 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-help (Deprexis)
Number of subjects: 229
Study 31651403 — intervention group
Group type: COMPARATOR
Intervention: Active control (Web-based information about depression and depressive symptoms)
Number of subjects: 229
Study 30285673 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy (LTG)
Number of subjects: 200
Study 30285673 — intervention group
Group type: COMPARATOR
Intervention: Conventional open total gastrectomy (OTG)
Number of subjects: 200
Study 26766027 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 74
Study 26766027 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS&BES
Number of subjects: 74
Study 26766027 — intervention group
Group type: COMPARATOR
Intervention: EES&BES
Number of subjects: 74
Study 25196873 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF), specific dosage and duration not mentioned
Number of subjects: 0
Study 25196873 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment, specific dosage and duration not mentioned
Number of subjects: 0
Study 21898022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 10
Study 21898022 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 10
Study 21898022 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoke
Number of subjects: 10
Study 21898022 — intervention group
Group type: COMPARATOR
Intervention: Urban city air
Number of subjects: 10
Study 19423613 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 138
Study 19423613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 138
Study 18061712 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg
Number of subjects: 207
Study 18061712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 15692468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% applied twice daily for 2 years
Number of subjects: 91
Study 15692468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 91
Study 11849199 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin on course 2
Number of subjects: 15
Study 11849199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin on course 2
Number of subjects: 15
Study 11849199 — intervention group
Group type: COMPARATOR
Intervention: In vitro carboplatin and cisplatin (10‐100 microm)
Number of subjects: 15
Study 11849199 — intervention group
Group type: COMPARATOR
Intervention: Human liver microsomes
Number of subjects: 15
Study 9925131 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio of 60:40
Number of subjects: 17
Study 9925131 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio of 40:60
Number of subjects: 17
Study 9925131 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio of 20:80
Number of subjects: 17
Study 9925131 — intervention group
Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 17
Study 7758229 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (0.04 +/- 0.01 IU/kg daily) for 12 months
Number of subjects: 38
Study 7758229 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (0.04 +/- 0.01 IU/kg daily) for 18 months
Number of subjects: 38
Study 7758229 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 38
Study 2139340 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 100 mg
Number of subjects: 18
Study 2139340 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 100, 200, or 300 mg
Number of subjects: 18
Study 2139340 — intervention group
Group type: COMPARATOR
Intervention: Xamoterol (various doses)
Number of subjects: 18
Study 2139340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7000149 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. BCG immunotherapy
Number of subjects: 182
Study 7000149 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 182
Study 7000149 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. BCG
Number of subjects: 182
Study 7000149 — intervention group
Group type: COMPARATOR
Intervention: Irradiated leukaemic blast cells
Number of subjects: 182
Study 7000149 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (both groups)
Number of subjects: 182
Study 30741563 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA SF‐8
Number of subjects: 1380
Study 30741563 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA SF‐10
Number of subjects: 1380
Study 30741563 — intervention group
Group type: COMPARATOR
Intervention: Original DPA scale
Number of subjects: 1380
Study 27250634 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity (high baseline multimorbidity score)
Number of subjects: 156
Study 27250634 — intervention group
Group type: EXPERIMENTAL
Intervention: Work functioning trajectories (increasing, low, medium, high scores)
Number of subjects: 156
Study 27697801 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg twice per day
Number of subjects: 80
Study 27697801 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 24773830 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 (7 mg, one daily capsule taken orally for 10 days each month for 3 consecutive months)
Number of subjects: 244
Study 24773830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 244
Study 22676715 — intervention group
Group type: EXPERIMENTAL
Intervention: PDX/GOS (4 g/L prebiotic blend of polydextrose and galactooligosaccharides)
Number of subjects: 419
Study 22676715 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS (4 g/L galactooligosaccharides)
Number of subjects: 419
Study 22676715 — intervention group
Group type: COMPARATOR
Intervention: Control (Enfamil® LIPIL®)
Number of subjects: 419
Study 19638976 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (UFT) with tamoxifen (TAM) for 2 years
Number of subjects: 377
Study 19638976 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, fluorouracil (CMF) with tamoxifen (TAM) for 6 cycles
Number of subjects: 377
Study 19638976 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (UFT)
Number of subjects: 377
Study 19638976 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, fluorouracil (CMF)
Number of subjects: 377
Study 17685197 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton for anxiety (n = 50)
Number of subjects: 100
Study 17685197 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM‐IV for depression (n = 50)
Number of subjects: 100
Study 16335040 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching gel (Perfect Bleach)
Number of subjects: 60
Study 16335040 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide bleaching gel (Viva Style)
Number of subjects: 60
Study 16335040 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 60
Study 16335040 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% hydrogen peroxide whitening strips (Crest Whitestrips Supreme)
Number of subjects: 60
Study 16335040 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study 11995742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult day care center (experimental group)
Number of subjects: 212
Study 11995742 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 212
Study 10403690 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus combination chemotherapy (IEP regimen: ifosfamide 3 gm/m2 IV with mesna uroprotection, epirubicin 60 mg/m2 IV on day 1 and cisplatin 60 mg/m2 IV on day 2)
Number of subjects: 287
Study 10403690 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus combination chemotherapy (MVP regimen: mitomycin-C 8 mg/m2, cisplatin 100 mg/m2 IV on day 1, vinblastine 4 mg/m2 IV on days 1 and 15)
Number of subjects: 287
Study 10403690 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 287
Study 7720887 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy and doxorubicin‐based chemotherapy with tamoxifen
Number of subjects: 61
Study 7720887 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy and doxorubicin‐based chemotherapy without tamoxifen
Number of subjects: 61
Study 2048589 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance index
Number of subjects: 350
Study 2048589 — intervention group
Group type: COMPARATOR
Intervention: Systolic/diastolic ratio
Number of subjects: 350
Study 2048589 — intervention group
Group type: COMPARATOR
Intervention: Pulsatility index
Number of subjects: 350
Study 2048589 — intervention group
Group type: COMPARATOR
Intervention: Diastolic average ratio
Number of subjects: 350
Study 7239725 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchor sleep taken at the same time each day (00.00-04.00; 04.00-08.00; 08.00-12.00 or 12.00-16.00) with irregular other sleep periods
Number of subjects: 0
Study 7239725 — intervention group
Group type: COMPARATOR
Intervention: Irregular sleeping routines (single randomly-timed 8-hour sleep or two randomly-arranged 4-hour sleep periods)
Number of subjects: 0
Study 7239725 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (irregular sleep without anchor sleep)
Number of subjects: 0
Study 30896819 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-lncRNA signature (DIAPH2 antisense RNA 1, FOXN3 antisense RNA 2, long intergenic non-protein coding RNA 652, maternally expressed 3, RHPN1 antisense RNA 1)
Number of subjects: 0
Study 30896819 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scoring system based on prognostic lncRNAs
Number of subjects: 0
Study 30896819 — intervention group
Group type: EXPERIMENTAL
Intervention: KEGG pathway analysis of target genes of the five prognostic lncRNAs
Number of subjects: 0
Study 30701884 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (monoclonal antibodies to IL-1β)
Number of subjects: 0
Study 30701884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26585409 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic review
Number of subjects: 16
Study 26585409 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic review plus social interaction intervention
Number of subjects: 16
Study 26585409 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic review without social intervention
Number of subjects: 16
Study 26585409 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interaction intervention
Number of subjects: 16
Study 26585409 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 16
Study 26585409 — intervention group
Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 16
Study 24686347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (8 mm Hg)
Number of subjects: 43
Study 24686347 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12 mm Hg)
Number of subjects: 43
Study 22309001 — intervention group
Group type: COMPARATOR
Intervention: Knows race only
Number of subjects: 71
Study 22309001 — intervention group
Group type: EXPERIMENTAL
Intervention: Knows education only
Number of subjects: 71
Study 22309001 — intervention group
Group type: EXPERIMENTAL
Intervention: Knows race and education
Number of subjects: 71
Study 22309001 — intervention group
Group type: EXPERIMENTAL
Intervention: Knows neither
Number of subjects: 71
Study 19438740 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 175
Study 19438740 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (Group 1)
Number of subjects: 175
Study 19438740 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (Group 2)
Number of subjects: 175
Study 19438740 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 175
Study 18161400 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib, 120 mg
Number of subjects: 22
Study 18161400 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid, 500 mg every 8 hours
Number of subjects: 22
Study 18161400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14691441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (1.5mg/kg infused in 10 minutes)
Number of subjects: 140
Study 14691441 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (10mg/kg infused in 30 minutes)
Number of subjects: 140
Study 14691441 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (500 microg infused in 20 minutes)
Number of subjects: 140